Mexiletine for the Treatment of Muscle Cramps in ALS
The purpose of this study is to determine if mexiletine is effective for the treatment of muscle cramps in Amyotrophic Lateral Sclerosis (ALS).
Muscle Cramps in Amyotrophic Lateral Sclerosis
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Mexiletine for the Treatment of Muscle Cramps in ALS|
- Cramp diary [ Time Frame: Daily during the 6 week study ] [ Designated as safety issue: No ]Daily recording of number of muscle cramps that occurred in the last 24 hours.
|Study Start Date:||May 2013|
|Estimated Study Completion Date:||October 2015|
|Estimated Primary Completion Date:||October 2015 (Final data collection date for primary outcome measure)|
Active Comparator: Mexiletine
Mexiletine, capsule, 150mg, PO BID, 14 days
Sodium channel blocker
Other Name: Mexetil
Placebo Comparator: Placebo
Placebo, capsule, PO BID, 14 days
Other Name: Sugar pill
Many ALS patients suffer from painful muscle cramps, but unfortunately we do not have any medication proven to help muscle cramps in ALS. Reducing the pain caused by cramps - which can be debilitating - could help people living with ALS.
Muscle cramps are sudden, painful, and involuntary contractions of a muscle. They are caused by nerve dysfunction. When we examine nerves and muscles electrically, we see cramps as bursts of high-frequency (up to150 Hz) firing of the motor nerve cells. Cramps in ALS are believed to be the result of an increase of persistent sodium currents in the sick lower motor nerve cells.
A medication called Quinine was for many years the commonly used drug for controlling cramps in ALS, but the FDA has advised against its use for cramps because of its potential risks (e.g., death). Today there is no agreement on how to treat cramps in the ALS. The American Academy of Neurology recently encouraged further studies of the treatment of muscle cramps and suggested lidocaine as one of a few drugs of special interest.
Mexiletine is a medication closely related to lidocaine that can be taken by mouth (instead of being injected). Mexiletine stops the type of sodium currents that are thought to cause muscle cramps. Mexiletine is a relatively older medication that has been extensively studied in humans. It has been shown to reduce the electrical measures of muscle cramps for other disease conditions. For example, in patients with another severe nerve disease - Machado-Joseph disease (SCA3) - mexiletine treatment led to a decrease in the average number of muscle cramps from 24 to 3 cramps per month.. The safety profile of mexiletine is good, with the most frequent side effects being nausea or other abdominal symptoms. These side effects are rare at the doses (300 mg/day) used in this study. In patients with normal heart function, mexiletine has a minimal effect on heart rhythm. In previous clinical trials, no subject developed any serious heart rate problem.
Using multiple sites within the State of California we will quickly enroll a small number (N=30) of ALS patients with severe muscle cramps. The study is a double-blinded, placebo controlled (i.e., the investigator and the participant does not know if the pills contain mexiletine or placebo), crossover (all subjects receive two weeks of mexiletine and two weeks of placebo) study.
After a one week run in, participants will be evaluated on their ability to fill out the cramp diary. Participants who filled out their diary will be randomly assigned to either mexiletine or placebo for their first two weeks. For the first three days of each 2-week period, one 150mg capsule will be taken at bed time. For day 4 to 14 one capsule twice per day will be taken. Each treatment period will be 2 weeks with an intervening 1 week washout period - for a total study length of 6 weeks. Safety will be monitored with liver function studies and EKG's.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01811355
|Contact: Bjorn Oskarsson, MD||916 734 email@example.com|
|Contact: Michelle Cregan||(916) firstname.lastname@example.org|
|United States, California|
|UCD Telehealth Network - Lake Almanor Clinic||Enrolling by invitation|
|Chester, California, United States, 96020|
|UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program||Recruiting|
|La Jolla, California, United States, 92093|
|Contact: Ivy Chippendale 858-246-0247 email@example.com|
|Contact: Aaryn Belfer 858-246-0247 firstname.lastname@example.org|
|Principal Investigator: John Ravits, MD|
|UCLA Neuromuscular Research Program||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Clara Sam 310-825-5232 email@example.com|
|Principal Investigator: Martina Wiedau-Pazos, MD|
|UCD Telehealth Network||Recruiting|
|One hundred sites, California, United States, Various|
|Contact: Bjorn Oskarsson, MD 916-734-6304 firstname.lastname@example.org|
|Contact: Michelle Cregan 9167346304 email@example.com|
|Principal Investigator: Bjorn Oskarsson, MD|
|UC Irvine Health ALS & Neuromuscular Center||Recruiting|
|Orange, California, United States, 92868|
|Contact: Brian Minton 714-456-8520 firstname.lastname@example.org|
|Contact: Veronica Martin 7144562332 email@example.com|
|Principal Investigator: Tahseen Mozaffar, MBBS|
|UC, Davis Medical Center ALS Clinic||Recruiting|
|Sacramento, California, United States, 95817|
|Contact: Bjorn Oskarsson, MD 916-734-3588 firstname.lastname@example.org|
|Contact: Nanette Joyce, DO 9167346304 email@example.com|
|Principal Investigator: Bjorn Oskarsson, MD|
|Principal Investigator:||Bjorn Oskarsson, MD||UC Davis|